Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan plus pembrolizumab versus physician's choice chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer
NL-OMON60590Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Sacituzumab govitecan + pembrolizumab with Treatment of physician's choice chemotherapy + pembrolizumab (2 arms). Primary endpoint: Progression-free survival. Started Dec 2022; status: active, not recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON60590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60590.